PTC Therapeutics, Inc. (PTCT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$69.30-2.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Total revenue reaches $1.08-$1.18 billion in 2026: FY26 revenue guidance $850M-$950M vs $1.08B-$1.18B target.
PTC grew revenue 43% last quarter. They aim for $1.13 billion in 2026. Product sales rose from $153 million to $225 million. Costs are controlled within $680-$720 million. The company is buying back shares with new notes.
PTC still loses money and has negative free cash flow. New financial obligations may pressure cash. Revenue growth may slow from current high levels.
The price is about 11% above our fair value near $83. Analysts expect 36% revenue growth. Our fair value is below the Street median, reflecting cautious optimism.
Breaks if: Capital moves worsen financial health or dilute shareholders
Breaks if: Expenses exceed $720 million in FY26
Product revenue falls below $750 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a long-term thesis on a company with a strong growth trajectory in the healthcare sector. The current state reflects a mix of strong recent financial performance and a high valuation compared to peers.
The market appears to have priced in a durable premium for PTCT, suggesting that investors expect continued strong performance. However, there is an expectations gap, indicating that some future growth may not be fully reflected in current valuations.
Management is focused on increasing revenue and managing expenses, with recent results showing strong revenue growth. However, the mixed status of expense management suggests some uncertainty in maintaining profitability.
Key factors include potential changes in guidance during the next earnings call and the overall health of the healthcare sector. Performance of sector leaders could influence PTCT's trajectory.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook for revenue. Additionally, the acquisition of the ST-920 Fabry gene therapy asset enhances the R&D pipeline. This acquisition is expected to advance growth potential for the company.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Total revenue falls below $1.08 billion in FY26
Raise full-year 2026 total revenue guidance to $1.18 to $1.28 billion, driven by product revenue growth and collaboration milestones.
Stated as a priority in 3 of last 3 quarters. Management raised full-year 2026 total revenue guidance from $1.08-$1.18 billion in 2026-Q1 to $1.18-$1.28 billion in 2026-Q2, with product revenue guidance raised from $750-$850 million to $850-$950 million. Reported total revenue grew from $272.6 million in 2026-Q1 to $360.5 million in 2026-Q2. The trajectory is delivering consistent revenue growth and upward guidance revisions.
“Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million.”
“Total product revenue guidance raised to $750 to $850 million, with expected total revenue of $1.08 to $1.18 billion.”
“Full-year 2026 product revenue of $700 to $800 million, representing a 19 to 36% increase from 2025.”
Overall, PTCT's long-term thesis remains intact, supported by strong recent performance but tempered by high valuation and mixed fundamentals. Not investment advice.